Yuji SakaiMy goal is to track the 500 world's best companies, and we use a few lists as a proxy. Every dividend aristocrat and champion, including foreign ones (25-plus year dividend growth streaks). Top 100 holdings in VIG (aristocrat and future aristocrat ETF). Top 100 holdings in SCHD (gold standard high-yield blue-chip ETF). Top 100 holdings in IWY (gold standard growth ETF). A recent addition is Gilead Sciences (NASDAQ:GILD), which many people have asked me about recently, as the yield has risen ...

While it tends to fly under the radar for many people, the biotech industry has seen a resurgence in investor interest over the last couple of years. While there could be several reasons for this, such as the COVID-19 pandemic bringing the value of biotechnology to the forefront or even the expansion of education in the biosciences, the fact remains – biotech is getting more attention than ever before. Nowadays, both institutional and retail investors are discussing which are the best biotech stocks to buy ...

Gilead Sciences, Inc. (GILD) announced positive interim results from the ongoing ASSURE study on pipeline candidate seladelpar. ASSURE is an open-label study evaluating the long-term safety and efficacy of seladelpar, a once-daily potent and selective peroxisome proliferator-activated receptor (PPAR) delta agonist or delpar. Seladelpar is a first-in-class oral, selective PPAR-delta agonist or delpar is being evaluated for treating primary biliary cholangitis (PBC). The study enrolled adult patients with PBC ...

Gilead Sciences, Inc. (NASDAQ:GILD) RBC Capital Markets Global Healthcare Conference May 15, 2024 10:30 AM ET Company Participants Johanna Mercier - Chief Commercial Officer Conference Call Participants Brian Abrahams - RBC Capital Markets Brian Abrahams Senior Biotech Analyst at RBC Capital Markets. We're really pleased to have our next presenting company, Gilead, represented by their Chief Commercial Officer, Johanna Mercier. Johanna, thanks again for joining us. Johanna Mercier Thanks, Brian, and hi, eve ...

Gilead Sciences, Inc. (NASDAQ:GILD) BofA Securities 2024 Health Care Conference May 14, 2024 2:20 PM ET Company Participants Geoff Meacham - Bank of America Securities Conference Call Participants Andrew Dickinson - Chief Financial Officer Geoff Meacham For the first day of the BofA Healthcare Conference. My name is Geoff Meacham. I'm the senior biopharma analyst here. We're thrilled today to have Gilead Sciences. And with me on stage is CFO, Andy Dickinson. Andy, good to see you. Andrew Dickinson Thank yo ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ________ to ________ Commission File No. 0-19731 GILEAD SCIENCES, INC. (Exact Name of Registrant as Specified in Its Charter) Delaware 94-3047598 (State or Other Jurisdi ...

Gilead Sciences, Inc. (GILD) reported better-than-expected results in the first quarter, as its loss was narrower than expected and sales beat estimates.GILD’s first-quarter adjusted loss per share of $1.32 per share was narrower than the Zacks Consensus Estimate of a loss of $1.49. In the year-ago quarter, the company reported adjusted earnings of $1.37 per share.The year-over-year decrease was due to an acquired in-process research and development (IPR&D) charge of $3.9 billion, or $3.14 per share, relate ...

Gilead Sciences, Inc. (NASDAQ:GILD) Q1 2024 Earnings Conference Call April 25, 2024 4:30 PM ET Company Participants Jacquie Ross - Vice President, Investor Relations Daniel O'Day - Chairman and Chief Executive Officer Johanna Mercier - Chief Commercial Officer Merdad Parsey - Chief Medical Officer Andrew Dickinson - Chief Financial Officer Cindy Perettie - Executive Vice President, Kite Conference Call Participants Chris Schott - JPMorgan Daina Graybosch - Leerink Partners Umer Raffat - Evercore ISI Tyler V ...

Q124 Financial Results A p r i l 2 5 , 2 0 2 4 Forward-Looking Statements Statements included in this presentation that are not historical in nature are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Gilead cautions readers that forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially. These risks and uncertainties include those relating to: Gilead’s ability to achieve its anticipate ...

For the quarter ended March 2024, Gilead Sciences (GILD) reported revenue of $6.69 billion, up 5.3% over the same period last year. EPS came in at -$1.32, compared to $1.37 in the year-ago quarter.The reported revenue represents a surprise of +5.59% over the Zacks Consensus Estimate of $6.33 billion. With the consensus EPS estimate being -$1.49, the EPS surprise was +11.41%.While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street ...